Peripheral Vascular Devices – Market Insights – Europe Part 2

The European PV device will grow modestly through 2032. Market expansion will be driven by an increasing PAD patient pool, adoption of drug-eluting technologies, and a rising preference for the endovascular approach over open surgery; however, declining ASPs and rising pricing competition will somewhat restrict revenue growth.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in Europe from 2019 through 2032.

Drug-eluting technologies and favorable reimbursement in countries like Belgium for endovascular procedures will drive growth of these devices.

How will the latest FDA guidelines on the use of paclitaxel-coated devices affect the European market?

To what degree will DES and DCBs be adopted in covered geographies over the forecast period?

How will the adoption of DES and DCBs impact the competitive landscape?

Developments in endovascular interventions are focusing on treating the lower extremities.

How has the expanded indication for endovascular interventions impacted the PV device market?

What new products are going to be available in the market, and how will they change the competitive landscape?

Will DCBs or DES become the first line of solution for BTK lesions?

Mergers and acquisitions involving big competitors will lead to shifts in the market going forward.

What acquisitions have occurred to allow companies to better position themselves to enter the DCB, percutaneous thrombectomy device, or atherectomy device markets?

How are competitors leveraging company and product portfolio acquisitions to expand their product offerings?

Budgetary constraints and insufficient reimbursement in some segments continue to affect the European PV device market.

To what extent will the lack of reimbursement affect the adoption of premium-priced devices like lithotripsy balloons and intravascular ultrasound?

How fast will ASPs erode and which countries will experience the greatest erosion?

What strategies are the competitors adopting to navigate the challenging cost-constrained European PV device market?

Table of contents

Peripheral Vascular Devices - Market Insights - Europe Part 2

Mohd Parvez

Vijay Motwani is a research associate on the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in the dialysis access treatment device and transcatheter embolization and occlusion device markets. Vijay holds a Bachelor’s degree in Pharmaceutical Sciences from Bharati Vidyapeeth Deemed University and a Master’s degree in Pharmaceutical Quality Assurance from the Manipal Academy of Higher Education, Manipal.

Contact sales Login to access report

Back to all Medtech Insights reports